In conclusion, combined GIPR/GLP1R agonism additively attenuates hepatic steatosis and lowers hepatic inflammation, ameliorating liver injury during the development of NAFLD in E3L.CETP mice. The gene discussed is CETP; the disease is metabolic dysfunction-associated steatotic liver disease.